Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

Abstract Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT...

Full description

Bibliographic Details
Main Authors: Jiaying Wu, Fankai Meng, Yang Cao, Yicheng Zhang, Xiaojian Zhu, Na Wang, Jue Wang, Lifang Huang, Jianfeng Zhou, Yi Xiao
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00523-2

Internet

https://doi.org/10.1038/s41408-021-00523-2

Similar Items